Cetilistat (ATL-962) is a novel gastrointestinal lipase inhibitor developed by Alizyme in the United Kingdom and subsequently licensed worldwide by "Norgina BV". Sinrisat is undergoing phase 3 clinical trials in the United States. In Japan, shinlistat was approved as a treatment for obesity in September 2013 in collaboration with Takeda Pharmaceutical co. The product is called "Oblean".
Xinli company he is a long-term and strong specificity gastrointestinal lipase inhibitor, it through the stomach and small lumen inside the stomach lipase and the activity of pancreatic lipase serine parts forming covalent bonds make enzyme inactivation and play a role of treatment, the deactivation of the enzyme in the food can not be mainly triglyceride hydrolysis of fats to absorbable free fatty acids and single acylglycerol. Undigested triglycerides are not absorbed by the body, leading to reduced calorie intake and weight control. The major advantages of cetilistat are that it does not affect the activities of other enzymes in the gastrointestinal tract, does not suppress appetite, does not require dietary restriction, does not act on the nervous system, and is not absorbed, i.e. does not enter the bloodstream. After cetilistat is administered, the phenomenon of oily defecation (floating oil droplets on water surface) can occur 24 hours after cetilistat is administered, that is, the elimination of undigested fat.
According to statistical analysis by the Organization for Economic Cooperation and Development (OECD), the number of obese adults in the world's seven major pharmaceutical markets was about 125 million in 2008. On this trend, the number of obese adults in the market will reach 143 million by 2018. Suppose only a fraction of these obese people get treatment. It will increase the market value of the world's seven largest markets from $9 billion to $11 billion between 2008 and 2018. It can be seen that the market prospect of New Listat is very considerable.
China
